Nifty
Sensex
:
:
10767.40
36330.65
-73.25 (-0.68%)
-233.23 (-0.64%)

Pharmaceuticals & Drugs

Rating :
60/99  (View)

BSE: 500087 | NSE: CIPLA

457.00
-1.65 (-0.36%)
19-Sep-2019 | 9:59AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  458.65
  •  461.95
  •  456.10
  •  458.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  228682
  •  1045.08
  •  678.45
  •  449.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 36,994.93
  • 23.80
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 40,692.35
  • 0.65%
  • 2.40

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.70%
  • 3.29%
  • 16.15%
  • FII
  • DII
  • Others
  • 1%
  • 15.57%
  • 27.29%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 7.60
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.33
  • 5.82
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 5.08
  • 15.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.14
  • 36.81
  • 38.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 3.76
  • 3.37

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.25
  • 18.38
  • 17.17

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
3,989.02
3,938.99
1.27%
4,403.98
3,697.97
19.09%
4,007.54
3,913.82
2.39%
4,011.90
4,082.41
-1.73%
Expenses
3,084.38
3,212.62
-3.99%
3,442.93
3,141.10
9.61%
3,299.87
3,095.16
6.61%
3,309.68
3,278.02
0.97%
EBITDA
904.64
726.37
24.54%
961.05
556.87
72.58%
707.67
818.66
-13.56%
702.22
804.39
-12.70%
EBIDTM
22.68%
18.44%
21.82%
15.06%
17.66%
20.92%
17.50%
19.70%
Other Income
78.37
170.11
-53.93%
95.36
40.01
138.34%
78.53
52.93
48.37%
132.57
113.33
16.98%
Interest
52.12
35.09
48.53%
44.78
35.20
27.22%
44.19
9.15
382.95%
44.37
42.02
5.59%
Depreciation
268.00
241.00
11.20%
510.28
284.82
79.16%
293.13
522.35
-43.88%
281.90
302.22
-6.72%
PBT
662.89
620.39
6.85%
501.35
199.34
151.50%
448.88
340.09
31.99%
508.52
573.48
-11.33%
Tax
192.24
173.71
10.67%
127.75
46.15
176.81%
125.68
-64.23
-
142.39
137.42
3.62%
PAT
470.65
446.68
5.37%
373.60
153.19
143.88%
323.20
404.32
-20.06%
366.13
436.06
-16.04%
PATM
11.80%
11.34%
8.48%
4.14%
8.06%
10.33%
9.13%
10.68%
EPS
5.93
5.60
5.89%
4.56
2.22
105.41%
4.12
4.98
-17.27%
4.68
5.25
-10.86%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,412.44
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
Net Sales Growth
4.98%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
 
Cost Of Goods Sold
5,556.89
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
Gross Profit
10,855.55
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
GP Margin
66.14%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
Total Expenditure
13,136.86
13,494.26
12,329.33
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
Power & Fuel Cost
-
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
% Of Sales
-
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
Employee Cost
-
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
% Of Sales
-
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
Manufacturing Exp.
-
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
% Of Sales
-
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
General & Admin Exp.
-
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
% Of Sales
-
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
Selling & Distn. Exp.
-
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
% Of Sales
-
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
Miscellaneous Exp.
-
855.40
595.99
645.54
83.99
497.67
441.10
355.12
194.07
111.96
326.48
% Of Sales
-
5.23%
3.93%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
EBITDA
3,275.58
2,868.15
2,826.38
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
EBITDA Margin
19.96%
17.53%
18.65%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
Other Income
384.83
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
Interest
185.46
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
Depreciation
1,353.31
1,097.15
1,322.82
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
PBT
2,121.64
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
Tax
588.06
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
Tax Rate
27.72%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
PAT
1,533.58
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
PAT before Minority Interest
1,594.24
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
Minority Interest
60.66
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
PAT Margin
9.34%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
PAT Growth
6.48%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
 
Unadjusted EPS
19.29
18.97
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
Share Capital
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
Total Reserves
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
Non-Current Liabilities
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
Secured Loans
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
Unsecured Loans
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
Long Term Provisions
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
Current Liabilities
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
Trade Payables
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
Other Current Liabilities
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
Short Term Borrowings
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
Short Term Provisions
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
Total Liabilities
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
Net Block
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
Gross Block
13,665.08
13,042.25
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
Accumulated Depreciation
4,108.55
2,816.17
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
Non Current Assets
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
Capital Work in Progress
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
Non Current Investment
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
Long Term Loans & Adv.
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
Other Non Current Assets
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
Current Assets
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
Current Investments
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
Inventories
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
Sundry Debtors
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
Cash & Bank
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
Other Current Assets
1,566.48
476.27
418.17
437.05
858.67
630.63
468.31
622.17
726.59
2,537.33
Short Term Loans & Adv.
1,150.49
1,122.86
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
Net Current Assets
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
Total Assets
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
PBT
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
Adjustment
1,268.77
1,298.59
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
Changes in Working Capital
-1,063.54
-783.25
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
Cash after chg. in Working capital
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
Net Fixed Assets
-187.17
-495.82
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
Net Investments
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
Others
-241.77
-7.10
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
Cash from Financing Activity
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
Net Cash Inflow / Outflow
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
Opening Cash & Equivalents
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
Closing Cash & Equivalent
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
ROA
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
ROE
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
ROCE
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
Fixed Asset Turnover
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
Receivable days
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
Inventory Days
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
Payable days
59.02
55.61
46.96
48.81
52.17
44.93
48.58
50.51
56.11
69.48
Cash Conversion Cycle
57.47
103.26
106.05
109.24
112.14
107.41
113.72
123.59
128.78
144.01
Total Debt/Equity
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
Interest Cover
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86

News Update


  • Stempeutics Research signs out-licensing deal with Cipla
    17th Sep 2019, 10:43 AM

    The deal consists of upfront payment and various milestones-based payments

    Read More
  • Cipla gets shareholders’ nod to raise Rs 3,000 crore
    19th Aug 2019, 09:39 AM

    The company's board had approved raising funds up to Rs 3,000 crore

    Read More
  • Cipla signs definitive agreement to acquire stake in subsidiary
    7th Aug 2019, 15:51 PM

    The transaction is expected to be completed within a month

    Read More
  • Cipla reports marginal rise in Q1 consolidated net profit
    7th Aug 2019, 15:34 PM

    Total consolidated income of the company decreased by 1.02% at Rs 4,067.39 crore for Q1FY20

    Read More
  • Cipla - Quarterly Results
    7th Aug 2019, 14:53 PM

    Read More
  • Cipla seeks favourable policies for domestic pharmaceutical industry
    29th Jul 2019, 10:37 AM

    The company has urged the government to increase fund allocation for the healthcare sector

    Read More
  • Cipla’s arm, Alvotech enter into exclusive partnership for commercialization of AVT02
    29th Jul 2019, 09:28 AM

    Alvotech will be responsible for development and supply of the product, while Cipla Gulf will be responsible for registration and commercialization

    Read More
  • Cipla’s arm acquires prescription drug ZEMDRI from Achaogen
    25th Jul 2019, 09:04 AM

    ZEMDRI is a once-daily novel IV aminoglycoside for the treatment of complicated urinary tract infections

    Read More
  • Cipla’s arm receives final approval for generic version of Pfizer’s Lyrica
    22nd Jul 2019, 09:22 AM

    InvaGen’s Pregabalin Capsules is AB-rated generic therapeutic equivalent version of Pfizer’s Lyrica

    Read More
  • USFDA completes inspection at Cipla’s API manufacturing facility in Bengaluru
    20th Jul 2019, 10:50 AM

    The inspection ended with 7 observations, none of which were repeat or related to data integrity

    Read More
  • Cipla’s arm enters into JV agreement with Jiangsu Acebright
    16th Jul 2019, 09:12 AM

    As per the agreement, Cipla EU will hold 80% stake and Acebright will hold 20% stake in the JV Company

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.